Directing immunometabolism presents new opportunities to modulate key cell types associated with the formation of foreign body response (FBR) capsule. Contrasting approaches directing immunometabolism are investigated to mitigate FBR: a broadly suppressive metabolic inhibitor (MI) cocktail comprised of 2‐deoxyglucose (2‐DG), metformin, and 6‐diazo‐5‐oxo‐l‐norleucine (DON) with daily systemic dosing regimen, and local weekly injection of the more narrowly focused tryptophan catabolizing IDO‐Gal3 fusion protein. Treatments significantly decrease FBR capsule formed around subcutaneously implanted cellulose disks. MI cocktail results in a substantially thinner FBR capsule (40% of control), while weekly local injection of IDO‐Gal3 also results in a thinner FBR capsule (69% of control). RNA‐sequencing capsule transcripts reveal MI cocktail promotes quiescence, with decreased antigen processing and presentation, T helper subset differentiation, and cytokine‐cytokine receptor pathway. IDO‐Gal3 promotes pro‐regenerative, alternatively activated M2‐like macrophages and T helper 2 cells, with increased expression of type 2 response‐associated genes (Il4, Il13, Arg1, Mrc1, Chil3, Gata3). IDO‐Gal3 decreases pro‐inflammatory innate sensing pathways, and C‐type lectin receptor, NOD‐like receptor, RIG‐I‐like receptor, and Toll‐like receptor signaling. This work helps define key gene targets and pathways concomitantly regulated in the FBR capsule during immunometabolic modulation compared to control FBR capsule.